[ad_1]
The federal government announced in a meeting with governors on Tuesday (20) that the Union will purchase 46 million doses of CoronaVac, a Butantan Institute vaccine produced in partnership with the Chinese company Sinovac. As a result, the federal government should invest R $ 2.6 billion by January.
The information that the agreement would be signed during the meeting was anticipated by the journalist José Roberto Burnier, from News.
Like the other vaccines tested in Brazil, CoronaVac is in the testing phase and its effectiveness has not yet been proven before the National Health Surveillance Agency (Anvisa) publishes its use.
São Paulo Governor João Doria (PSDB) and 23 other governors attended the meeting with Health Minister Eduardo Pazuello.
According to Pazuello, when the vaccine is approved, the doses will be distributed throughout Brazil through the National Immunization Program (PNI), which for decades has already guaranteed the success of national vaccination campaigns. “We have the experience of all the processes that involve this logistics, acquired over 47 years of PNI. The vaccines will reach Brazilians in all states ”, he guaranteed.
Before Tuesday’s announcement, the ministry’s forecast was to have 140 million doses in the first half of 2021:
- 40 million through the COVAX Facility initiative, led by the World Health Organization (WHO)
- 100 million doses via AstraZeneca / Oxford (in addition to these doses, in the second half, the government should produce 165 million doses of this immunizer).
Until an earlier meeting held with state health secretaries from across the country last week, the federal government had not included CoronaVac in the national vaccination program.
CoronaVac is in the third phase of testing. This Monday (20), the government of São Paulo declared that 35% of the 9,000 volunteers who participated in the tests in Brazil had mild adverse reactions. According to the government, there was no record of serious side effects, confirming the safety of the vaccine.
The information is part of a partial study presented at a press conference. However, the study has not been published in a scientific journal. There is no data yet on the effectiveness of CoronaVac. According to the government, this information will be released by the end of the year.